BACKGROUND: The impact of age on prognosis in advanced stage non-small cell lung cancer (NSCLC) may differ by sex. PATIENTS AND METHODS: Eligible patients (N=1590) from E1594, a 4-arm platinum-based chemotherapy trial, and E4599 (carboplatin/paclitaxel ± bevacizumab) chemotherapy arm were divided into male and female cohorts and separated into age groups of <60 or ≥60 years old. Eligible E4599 patients (N=850) were similarly separated by age and sex and by treatment (± bevacizumab). Survival was calculated separately for each cohort. RESULTS: The median survival time (MST) for women ≥60 years old treated with chemotherapy alone on E1594 and E4599 was 11.6 months versus 9.0 months for women <60 (p=0.03). MST was 7.4 and 8.3 months for men ≥60 and <60 years old respectively (NS). In E4599 the age <60 by bevacizumab treatment interaction was statistically significant (p=0.03) for women (younger had greater benefit), with no age effect in men. CONCLUSIONS: In this unplanned, exploratory subgroup analysis of advanced stage NSCLC ECOG trials, women ≥60 years old treated with chemotherapy live longer than men and younger women. In contrast, bevacizumab survival benefit was more pronounced in men of any age and in younger women on E4599.
BACKGROUND: The impact of age on prognosis in advanced stage non-small cell lung cancer (NSCLC) may differ by sex. PATIENTS AND METHODS: Eligible patients (N=1590) from E1594, a 4-arm platinum-based chemotherapy trial, and E4599 (carboplatin/paclitaxel ± bevacizumab) chemotherapy arm were divided into male and female cohorts and separated into age groups of <60 or ≥60 years old. Eligible E4599 patients (N=850) were similarly separated by age and sex and by treatment (± bevacizumab). Survival was calculated separately for each cohort. RESULTS: The median survival time (MST) for women ≥60 years old treated with chemotherapy alone on E1594 and E4599 was 11.6 months versus 9.0 months for women <60 (p=0.03). MST was 7.4 and 8.3 months for men ≥60 and <60 years old respectively (NS). In E4599 the age <60 by bevacizumab treatment interaction was statistically significant (p=0.03) for women (younger had greater benefit), with no age effect in men. CONCLUSIONS: In this unplanned, exploratory subgroup analysis of advanced stage NSCLC ECOG trials, women ≥60 years old treated with chemotherapy live longer than men and younger women. In contrast, bevacizumab survival benefit was more pronounced in men of any age and in younger women on E4599.
Authors: M D Mueller; J L Vigne; A Minchenko; D I Lebovic; D C Leitman; R N Taylor Journal: Proc Natl Acad Sci U S A Date: 2000-09-26 Impact factor: 11.205
Authors: H Sumino; T Nakamura; S Ichikawa; T Kanda; T Sakamaki; K Sato; I Kobayashi; R Nagai Journal: Atherosclerosis Date: 2000-01 Impact factor: 5.162
Authors: Rowan T Chlebowski; Garnet L Anderson; JoAnn E Manson; Ann G Schwartz; Heather Wakelee; Margery Gass; Rebecca J Rodabough; Karen C Johnson; Jean Wactawski-Wende; Jane Morley Kotchen; Judith K Ockene; Mary Jo O'Sullivan; F Allan Hubbell; Jason W Chien; Chu Chen; Marcia L Stefanick Journal: J Natl Cancer Inst Date: 2010-08-13 Impact factor: 13.506
Authors: Rowan T Chlebowski; Ann G Schwartz; Heather Wakelee; Garnet L Anderson; Marcia L Stefanick; JoAnn E Manson; Rebecca J Rodabough; Jason W Chien; Jean Wactawski-Wende; Margery Gass; Jane Morley Kotchen; Karen C Johnson; Mary Jo O'Sullivan; Judith K Ockene; Chu Chen; F Allan Hubbell Journal: Lancet Date: 2009-09-18 Impact factor: 79.321
Authors: Debra P Ritzwoller; Nikki M Carroll; Thomas Delate; Mark C Hornbrook; Lawrence Kushi; Erin J Aiello Bowles; Elizabeth T Loggers; Alex Menter Journal: J Thorac Oncol Date: 2014-05 Impact factor: 15.609
Authors: Corey J Langer; Shirish M Gadgeel; Hossein Borghaei; Vassiliki A Papadimitrakopoulou; Amita Patnaik; Steven F Powell; Ryan D Gentzler; Renato G Martins; James P Stevenson; Shadia I Jalal; Amit Panwalkar; James Chih-Hsin Yang; Matthew Gubens; Lecia V Sequist; Mark M Awad; Joseph Fiore; Yang Ge; Harry Raftopoulos; Leena Gandhi Journal: Lancet Oncol Date: 2016-10-10 Impact factor: 41.316
Authors: J Remon; E Molina-Montes; M Majem; P Lianes; D Isla; P Garrido; E Felip; N Viñolas; J de Castro; A Artal; M-J Sánchez Journal: Clin Transl Oncol Date: 2013-11-26 Impact factor: 3.405